OTIC News and Press, Otonomy Inc. From 11/03/21

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the third quarter 2021 and provide a corporate update at ...

Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing loss Supportive preclinical data to be presented for OTO-825 gene therapy and OTO-510 otoprotection program SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc...

Results published in Otology & Neurotology, a leading journal in field OTO-313 was well-tolerated and demonstrated a statistically significant higher proportion of responders than placebo across consecutive visits (Weeks 4 and 8) Patient enrollment in Pha...

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of previously disclosed clinical results from the successful OTO-413 Phase 1...

SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the appointment of Jill Broadfoot to its board of directors. “Jill is an excellen...

Start Time: 16:30 End Time: 16:55 Otonomy, Inc. (OTIC) Q2 2021 Earnings Conference Call August 04, 2021, 16:30 PM ET Company Participants David Weber - President and CEO Paul Cayer - Chief Financial and Business Officer Robert Uhl - MD Conference Call Participants Stacy Ku - Cowen and Company...

Otonomy (NASDAQ:OTIC): Q2 GAAP EPS of -$0.19 in-line. Revenue of $0.04M (+300.0% Y/Y) in-line. Outlook: Otonomy expects that GAAP operating expenses will be in the range of $46-$48M, and that non-GAAP operating expenses will be in the range of $38-$40M. Otonomy expects that its current cash, ...

OTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022 OTO-413 Phase 1/2 trial expansion in hearing loss ongoing with results expected in mid-2022 OTO-825 preclinical proof-of-concept results presented at ASGCT meeting; Pre-IND meeting comp...

Otonomy Inc. (NASDAQ:OTIC) traded today at a new 52-week low of $1.66. Approximately 335,000 shares have changed hands today, as compared to an average 30-day volume of 345,000 shares. Otonomy Inc. share prices have moved between a 52-week high of $6.98 and the current low of $1.66 and a...